STAT+: Biotech investor activism is on the rise
'Oh no, another Adam rant': True, but STAT's Adam Feuerstein says it's totally justified. It's reality check time in biotech.
This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.
It’s reality check time in biotech.
A recovery from this prolonged and painful market downturn will require a major attitude adjustment from biotech management teams. For some especially troubled companies, that means voluntarily shutting down. Everyone else needs to prune back R&D ambitions and become more mindful spenders of cash.
